Journal
BLOOD
Volume 113, Issue 5, Pages 1002-1005Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-04-152678
Keywords
-
Categories
Funding
- American Society of Clinical Oncology Young Investigator Award
- National Institutes of Health/National Cancer Institute [K23CA120708]
- D. Warren Brown Foundation
Ask authors/readers for more resources
Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897. (Blood. 2009;113:1002-1005)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available